This topic contains a solution. Click here to go to the answer

Author Question: Warfarin skin necrosis occurs within the first 2 to 3 days after starting warfarin therapy because: ... (Read 47 times)

krzymel

  • Hero Member
  • *****
  • Posts: 548
Warfarin skin necrosis occurs within the first 2 to 3 days after starting warfarin therapy because:
 
  a. The platelet count decreases to fewer than 100  109/L, and significant bleeding occurs.
  b. Protein C decreases significantly before full anticoagulation, and skin thrombosis results.
  c. Prothrombin decreases rapidly generating less thrombin, and significant bleeding occurs.
  d. Plasminogen increases, and rapid clot lysis occurs.

Question 2

An INR of 6.5 is obtained on a patient taking warfarin. All quality control is acceptable. What should be done?
 
  a. Report the result.
  b. Report only the PT in seconds and ignore the INR.
  c. Send an e-mail to the healthcare provider.
  d. Call the healthcare provider immediately.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

blakeserpa

  • Sr. Member
  • ****
  • Posts: 338
Answer to Question 1

ANS: B
Protein C has a 6-hour half-life, and so it rapidly decreases when warfarin therapy is begun, along with factor VII (both are vitamin Kdependent proteins). Full anticoagulation with warfarin is not obtained until factors X and prothrombin are decreased to less than 50, requANS: B
Protein C has a 6-hour half-life, and so it rapidly decreases when warfarin therapy is begun, along with factor VII (both are vitamin Kdependent proteins). Full anticoagulation with warfarin is not obtained until factors X and prothrombin are decreased to less than 50, requiring 4 to 7 days based on their half-lives. Because protein C is important in controlling clot formation, its decrease actually puts the patient in a prethrombotic state until full anticoagulation is obtained.
iring 4 to 7 days based on their half-lives. Because protein C is important in controlling clot formation, its decrease actually puts the patient in a prethrombotic state until full anticoagulation is obtained.

Answer to Question 2

ANS: D
The clinical laboratory scientist must immediately call the healthcare provider because this is a critical INR result and he or she must be able to intervene with appropriate patient care. The call must be documented according to the protocol established by clinical scientists in the laboratory. This is essential to prevent a bad outcome for the patient.





 

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

IgA antibodies protect body surfaces exposed to outside foreign substances. IgG antibodies are found in all body fluids. IgM antibodies are the first type of antibody made in response to an infection. IgE antibody levels are often high in people with allergies. IgD antibodies are found in tissues lining the abdomen and chest.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

In 1886, William Bates reported on the discovery of a substance produced by the adrenal gland that turned out to be epinephrine (adrenaline). In 1904, this drug was first artificially synthesized by Friedrich Stolz.

Did you know?

About 80% of major fungal systemic infections are due to Candida albicans. Another form, Candida peritonitis, occurs most often in postoperative patients. A rare disease, Candida meningitis, may follow leukemia, kidney transplant, other immunosuppressed factors, or when suffering from Candida septicemia.

For a complete list of videos, visit our video library